MCID: MYC017
MIFTS: 36

Mycobacterium Kansasii

Categories: Rare diseases

Aliases & Classifications for Mycobacterium Kansasii

MalaCards integrated aliases for Mycobacterium Kansasii:

Name: Mycobacterium Kansasii 20
Infection Due to Mycobacterium Kansasii 70
Mycobacterium Kansasii Infection 20
M. Kansasii 20

Classifications:



External Ids:

UMLS 70 C0275706

Summaries for Mycobacterium Kansasii

MalaCards based summary : Mycobacterium Kansasii, also known as infection due to mycobacterium kansasii, is related to septic arthritis and mycobacterium marinum. An important gene associated with Mycobacterium Kansasii is CD14 (CD14 Molecule), and among its related pathways/superpathways are Innate Immune System and Toll-like Receptor Signaling Pathway. The drugs Ofloxacin and Clofazimine have been mentioned in the context of this disorder. Affiliated tissues include lung, t cells and bone marrow, and related phenotype is hematopoietic system.

Wikipedia : 73 Mycobacterium kansasii is a bacterium in the Mycobacterium family. The genus includes species known to... more...

Related Diseases for Mycobacterium Kansasii

Diseases related to Mycobacterium Kansasii via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 248)
# Related Disease Score Top Affiliating Genes
1 septic arthritis 30.9 TLR2 CXCL8
2 mycobacterium marinum 30.8 TLR2 CXCL8
3 osteomyelitis 30.5 TLR2 NLRP3 CXCL8
4 lung disease 30.5 TLR2 FN1 CXCL8
5 silicosis 30.3 NLRP3 CXCL8
6 pleurisy 30.2 TLR2 CXCL8
7 mycobacterium chelonae 30.2 TLR2 CXCL8 CD14
8 tuberculous meningitis 30.1 TLR2 CXCL8
9 leukemia, acute monocytic 30.1 CXCL8 CD14
10 invasive aspergillosis 30.0 TLR2 CXCL8
11 fungal infectious disease 30.0 TLR2 CXCL8
12 pyoderma 29.9 NLRP3 CXCL8
13 pyoderma gangrenosum 29.9 NLRP3 CXCL8
14 exanthem 29.9 NLRP3 CXCL8
15 pulmonary alveolar proteinosis 29.8 GATA2 CXCL8
16 mycobacterium abscessus 29.8 TLR2 NLRP3 CXCL8
17 toxic shock syndrome 29.8 TLR2 CXCL8 CD14
18 amebiasis 29.8 TLR2 FN1 CXCL8
19 pneumoconiosis 29.7 NLRP3 FN1 CXCL8
20 aphthous stomatitis 29.6 TLR2 NLRP3 CXCL8
21 bone inflammation disease 29.6 TLR2 NLRP3 CXCL8
22 meningitis 29.6 TLR2 NLRP3 CXCL8
23 crohn's disease 29.6 TLR2 NLRP3 CXCL8
24 peritonitis 29.3 TLR2 NLRP3 CXCL8 CD14
25 inflammatory bowel disease 29.2 TLR2 NLRP3 CXCL8 CD14
26 acquired immunodeficiency syndrome 10.6
27 immune deficiency disease 10.5
28 tenosynovitis 10.5
29 mycobacterium tuberculosis 1 10.4
30 mycobacterium gordonae 10.4
31 myelodysplastic syndrome 10.4
32 lymphadenitis 10.4
33 pulmonary tuberculosis 10.4
34 pericarditis 10.3
35 cellulitis 10.3
36 mycobacterium fortuitum 10.3
37 mycobacterium xenopi 10.3
38 human immunodeficiency virus type 1 10.3
39 pancytopenia 10.3
40 systemic lupus erythematosus 10.2
41 respiratory failure 10.2
42 pneumonia 10.2
43 bronchiectasis 10.2
44 enterocolitis 10.2 CXCL8 CD14
45 croup 10.2 CXCL8 CD14
46 carpal tunnel syndrome 10.2
47 sarcoidosis 1 10.2
48 hemopericardium 10.2
49 frozen shoulder 10.2
50 bronchiolitis 10.2

Graphical network of the top 20 diseases related to Mycobacterium Kansasii:



Diseases related to Mycobacterium Kansasii

Symptoms & Phenotypes for Mycobacterium Kansasii

MGI Mouse Phenotypes related to Mycobacterium Kansasii:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.1 CD14 FN1 GATA2 NLRP3 PLCG1 TLR2

Drugs & Therapeutics for Mycobacterium Kansasii

Drugs for Mycobacterium Kansasii (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 21)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ofloxacin Approved Phase 3 82419-36-1 4583
2
Clofazimine Approved, Investigational Phase 3 2030-63-9 2794
3
Moxifloxacin Approved, Investigational Phase 3 354812-41-2, 151096-09-2 152946
4
Kanamycin Approved, Investigational, Vet_approved Phase 3 8063-07-8, 59-01-8 6032
5
Pyrazinamide Approved, Investigational Phase 3 98-96-4 1046
6
Bedaquiline Approved Phase 3 843663-66-1
7
Isoniazid Approved, Investigational Phase 3 54-85-3 3767
8
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
9
Ethambutol Approved Phase 3 74-55-5 3279 14052
10
Prothionamide Approved, Investigational Phase 3 14222-60-7 666418
11 Antibiotics, Antitubercular Phase 3
12 Cytochrome P-450 Enzyme Inhibitors Phase 3
13 Fluoroquinolones Phase 3
14 Antimetabolites Phase 3
15 Lipid Regulating Agents Phase 3
16 Anti-Bacterial Agents Phase 3
17 Norgestimate, ethinyl estradiol drug combination Phase 3
18 Anti-Infective Agents Phase 3
19 Antitubercular Agents Phase 3
20 Anti-Inflammatory Agents Phase 3
21 Hypolipidemic Agents Phase 3

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 STREAM: The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB Active, not recruiting NCT02409290 Phase 3 Regimen A locally-used WHO-approved MDR-TB regimen (2011 guideline);Moxifloxacin;Clofazimine;Ethambutol;Pyrazinamide;Isoniazid;Prothionamide;Kanamycin;Levofloxacin;Bedaquiline

Search NIH Clinical Center for Mycobacterium Kansasii

Genetic Tests for Mycobacterium Kansasii

Anatomical Context for Mycobacterium Kansasii

MalaCards organs/tissues related to Mycobacterium Kansasii:

40
Lung, T Cells, Bone Marrow, Lymph Node, Skin, Myeloid, Monocytes

Publications for Mycobacterium Kansasii

Articles related to Mycobacterium Kansasii:

(show top 50) (show all 1158)
# Title Authors PMID Year
1
Human pathogenic Mycobacterium kansasii (former subtype I) with zoonotic potential isolated from a diseased indoor pet cat, Japan. 61
33467980 2021
2
Mycobacterium kansasii Infection Presenting as an Invasive Endobronchial Occupancy. 61
33170021 2021
3
Prevalence and speciation of non-tuberculous mycobacteria among pulmonary and extrapulmonary tuberculosis suspects in South India. 61
33618276 2021
4
Analysis of pulmonary nodules caused by nontuberculous mycobacteriosis in 101 resected cases: multi-center retrospective study. 61
33717570 2021
5
Nouveau short-course therapy and morphism mapping for clinical pulmonary Mycobacterium kansasii. 61
33558291 2021
6
Pathogenic Determinants of the Mycobacterium kansasii Complex: An Unsuspected Role for Distributive Conjugal Transfer. 61
33578772 2021
7
Drug susceptibility distributions of Mycobacterium chimaera and other non-tuberculous mycobacteria. 61
33619057 2021
8
Detection of Mycobacterium kansasii using a combination of loop-mediated isothermal amplification (LAMP) and lateral flow biosensors. 61
32880033 2021
9
Profile of Nontuberculous Mycobacteria in Patients Suspected of Tuberculosis and Drug-Resistant Tuberculosis. 61
33268938 2020
10
Septic Arthritis Caused by Mycobacterium Kansasii in a Bone Marrow Transplant Recipient. 61
32049768 2020
11
Systemic Mycobacterium kansasii Infection in Two Related Cats. 61
33218094 2020
12
Nontuberculous mycobacteria: A report of eighteen cases from a tertiary care center in India. 61
33154211 2020
13
Pulmonary and Skeletal Infection of Mycobacterium kansasii. 61
32780583 2020
14
Heterologous Production of 1-Tuberculosinyladenosine in Mycobacterium kansasii Models Pathoevolution towards the Transcellular Lifestyle of Mycobacterium tuberculosis. 61
33082253 2020
15
Successful cord blood transplantation for myelodysplastic syndrome complicated by Mycobacterium kansasii pneumonia. 61
32918515 2020
16
Comparison of a Novel Regimen of Rifapentine, Tedizolid, and Minocycline with Standard Regimens for Treatment of Pulmonary Mycobacterium kansasii. 61
32690646 2020
17
Correlation of Conservation of Sequence and Structures of Mycobacterial Hemerythrin-like Proteins with Evolutionary Relationship and Host Pathogenicity. 61
32954191 2020
18
Structural and Functional Characterization of Phosphatidylinositol-Phosphate Biosynthesis in Mycobacteria. 61
32389689 2020
19
Large Extracellular Cord Formation in a Zebrafish Model of Mycobacterium kansasii Infection. 61
32301995 2020
20
Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline: Executive Summary. 61
32628747 2020
21
Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. 61
32797222 2020
22
A Rare Case of Brodie's Abscess in HIV Patient Caused by Mycobacterium kansasii. 61
33014651 2020
23
Detection of clinically important non tuberculous mycobacteria (NTM) from pulmonary samples through one-step multiplex PCR assay. 61
32847517 2020
24
A case report of a male patient receiving treatment for anorexia nervosa and comorbid obsessive compulsive disorder who was later diagnosed with nontuberculosis Mycobacterium. 61
32710364 2020
25
Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. 61
32636299 2020
26
Treatment of pulmonary disease caused by Mycobacterium kansasii. 61
32505588 2020
27
Identification of mycobacteria species by molecular methods. 61
31863568 2020
28
Transposon mutagenesis in Mycobacterium kansasii links a small RNA gene to colony morphology and biofilm formation and identifies 9,885 intragenic insertions that do not compromise colony outgrowth. 61
32083796 2020
29
Chronic Tenosynovitis of the Upper Extremities Caused by Mycobacterium kansasii : A Clinical Case and Systematic Review of Literature. 61
32367915 2020
30
Mycobacterium kansasii arthritis of the elbow in an immunocompetent patient with a suspected soft-tissue tumor. 61
31427201 2020
31
Ethambutol-resistant Mycobacterium kansasii cervical lymphadenitis in an immunocompetent adult patient: A case report and literature review. 61
31890900 2020
32
Disseminated Mycobacterium kansasii infection in a white-tailed deer and implications for public and livestock health. 61
31845615 2020
33
Performance of Interferon-Gamma Release Assays in the Diagnosis of Nontuberculous Mycobacterial Diseases-A Retrospective Survey From 2011 to 2019. 61
33680977 2020
34
The Chemical Composition and Anti-mycobacterial Activities of Trachyspermum copticum and Pelargonium graveolens Essential Oils. 61
31657682 2020
35
Detection of non-tuberculous mycobacterial species using PCR-RFLP analysis in trans-tracheal washes in cattle and buffaloes with respiratory distress. 61
32849894 2020
36
Crystal structure of a hemerythrin-like protein from Mycobacterium kansasii and homology model of the orthologous Rv2633c protein of M. tuberculosis. 61
31913442 2020
37
Molecular Identification, and Characterization of Mycobacterium kansasii Strains Isolated from Four Tuberculosis Regional Reference Laboratories in Iran During 2016-2018. 61
32753913 2020
38
Comparison of in vitro Susceptibility of Mycobacteria Against PA-824 to Identify Key Residues of Ddn, the Deazoflavin-Dependent Nitroreductase from Mycobacterium tuberculosis. 61
32210596 2020
39
Comparative Genomic and Transcriptomic Analyses of Mycobacterium kansasii Subtypes Provide New Insights Into Their Pathogenicity and Taxonomy. 61
32266172 2020
40
Evaluation of Mycobacterium kansasii extracellular vesicles role in BALB/c mice immune modulatory. 61
32474490 2020
41
Cas12a/Guide RNA-Based Platform for Rapid and Accurate Identification of Major Mycobacterium Species. 61
31723010 2020
42
Incidence, Clinical Manifestation, Treatment Outcome, and Drug Susceptibility Pattern of Nontuberculous Mycobacteria in HIV Patients in Tehran, Iran. 61
32116435 2020
43
Drug susceptibility profile of Mycobacterium kansasii clinical isolates from Brazil. 61
31100506 2019
44
Identification of Non-Tuberculosis Mycobacteria by Line Probe Assay and Determination of Drug Resistance Patterns of Isolates in Iranian Patients. 61
31939254 2019
45
Chronic laryngitis caused by Mycobacterium Kansasii in a traveler. 61
30912581 2019
46
Case Report: Disseminated Mycobacterium kansasii Disease in a Patient with Anti-Interferon-Gamma Antibody. 61
31549614 2019
47
Invasive Endobronchial Mycobacterium kansasii Infection. 61
31237769 2019
48
Phenolic N-monosubstituted carbamates: Antitubercular and toxicity evaluation of multi-targeting compounds. 61
31401536 2019
49
Changing epidemiology of nontuberculous mycobacterial lung disease over the last two decades in a region of the Basque country. 61
31720298 2019
50
Profile of patients with pulmonary non-tuberculous mycobacterial disease mimicking pulmonary tuberculosis. 61
31813432 2019

Variations for Mycobacterium Kansasii

Expression for Mycobacterium Kansasii

Search GEO for disease gene expression data for Mycobacterium Kansasii.

Pathways for Mycobacterium Kansasii

Pathways related to Mycobacterium Kansasii according to GeneCards Suite gene sharing:

(show all 24)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.67 TLR2 PLCG1 NLRP3 FN1 CXCL8 CD14
2
Show member pathways
12.85 TLR2 PLCG1 NLRP3 CXCL8 CD14
3
Show member pathways
12.47 TLR2 NLRP3 CXCL8 CD14
4
Show member pathways
12.45 TLR2 NLRP3 CXCL8 CD14
5
Show member pathways
12.05 PLCG1 CXCL8 CD14
6 12.05 TLR2 PLCG1 FN1
7
Show member pathways
12.04 TLR2 PLCG1 FN1 CD14
8
Show member pathways
12 TLR2 CXCL8 CD14
9 11.95 PLCG1 NLRP3 CXCL8 CD14
10 11.69 PLCG1 CXCL8 CD14
11
Show member pathways
11.67 TLR2 FN1 CXCL8 CD14
12 11.65 PLCG1 FN1 CXCL8
13 11.54 TLR2 PLCG1 FN1
14 11.46 NLRP3 CXCL8 CD14
15 11.43 PLCG1 CXCL8
16 11.4 FN1 CXCL8
17 11.39 PLCG1 NLRP3 FN1 CXCL8
18 11.3 TLR2 CXCL8
19 11.25 TLR2 CXCL8 CD14
20 11.23 FN1 CXCL8
21 11.1 FN1 CXCL8
22 10.97 TLR2 NLRP3
23 10.93 TLR2 FN1 CXCL8 CD14
24 10.82 FN1 CXCL8

GO Terms for Mycobacterium Kansasii

Biological processes related to Mycobacterium Kansasii according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.73 TLR2 GATA2 FN1 CXCL8
2 inflammatory response GO:0006954 9.67 TLR2 NLRP3 CXCL8 CD14
3 cellular response to lipopolysaccharide GO:0071222 9.65 NLRP3 CXCL8 CD14
4 positive regulation of angiogenesis GO:0045766 9.63 PLCG1 GATA2 CXCL8
5 positive regulation of interleukin-8 production GO:0032757 9.55 TLR2 CD14
6 positive regulation of blood vessel endothelial cell migration GO:0043536 9.54 PLCG1 GATA2
7 toll-like receptor signaling pathway GO:0002224 9.52 TLR2 CD14
8 lipopolysaccharide-mediated signaling pathway GO:0031663 9.51 TLR2 CD14
9 MyD88-dependent toll-like receptor signaling pathway GO:0002755 9.49 TLR2 CD14
10 cellular response to lipoteichoic acid GO:0071223 9.4 TLR2 CD14
11 cellular response to diacyl bacterial lipopeptide GO:0071726 9.32 TLR2 CD14
12 toll-like receptor TLR6:TLR2 signaling pathway GO:0038124 9.26 TLR2 CD14
13 toll-like receptor TLR1:TLR2 signaling pathway GO:0038123 9.16 TLR2 CD14
14 cellular response to triacyl bacterial lipopeptide GO:0071727 8.96 TLR2 CD14
15 response to molecule of bacterial origin GO:0002237 8.8 TLR2 CXCL8 CD14

Molecular functions related to Mycobacterium Kansasii according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lipopolysaccharide binding GO:0001530 9.16 TLR2 CD14
2 peptidoglycan binding GO:0042834 8.96 TLR2 NLRP3
3 lipopeptide binding GO:0071723 8.62 TLR2 CD14

Sources for Mycobacterium Kansasii

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....